Purpose As no curative treatment for advanced pancreatic and biliary cancer with malignant ascites exists, new modalities possibly improving the response to available chemotherapies must be explored. This phase I study assesses the feasibility, tolerability and pharmacokinetics of a regional treatment of gemcitabine administered in escalating doses by the stop-Xow approach to patients with advanced abdominal malignancies (adenocarcinoma of the pancreas, n = 8, and cholangiocarcinoma of the liver, n = 1). Experimental design Gemcitabine at 500, 750 and 1,125 mg/m 2 was administered to three patients at each dose level by loco-regional chemotherapy, using hypoxic abdominal stop-Xow perfusion. This was achieved by an aorto-caval occlusion by balloon catheters connected to an extracorporeal circuit. Gemcitabine and its main metabolite 2Ј,2Ј-diXuorodeoxyuridine (dFdU) concentrations were measured by high performance liquid chromatography with UV detection in the extracorporeal circuit during the 20 min of stop-Xow perfusion, and in peripheral plasma for 420 min. Blood gases were monitored during the stop-Xow perfusion and hypoxia was considered stringent if two of the following endpoints were met: pH · 7.2, pO 2 nadir ratio ·0.70 or pCO 2 peak ratio ¸1.35. The tolerability of this procedure was also assessed. Results Stringent hypoxia was achieved in four patients. Very high levels of gemcitabine were rapidly reached in the extracorporeal circuit during the 20 min of stop-Xow perfusion, with C max levels in the abdominal circuit of 246 ( §37%), 2,039 ( §77%) and 4,780 ( §7.3%) g/ml for the three dose levels 500, 750 and 1,125 mg/m 2 , respectively. These C max were between 13 ( §51%) and 290 ( §12%) times higher than those measured in the peripheral plasma. 
Introduction
Cancer of the exocrine pancreas represents a major health burden in developed countries. In the United States, it was reported in 2000 as the fourth leading cause of cancerrelated death for both men and women, while in Europe it ranked sixth [1] . Because of diYculties in diagnosis, the aggressiveness of tumour growth and the lack of eVective systemic therapies, the one and Wve year survival rates remain below 25 and 5%, respectively [1, 2] .
Considering the very poor prognosis of advanced pancreatic cancer with malignant ascites, and the absence of eYcient new drugs, innovative modalities that may possibly improve, even modestly, the clinical response to available chemotherapies deserve exploration. A phase I study was therefore initiated, aiming at assessing the feasibility, tolerability and pharmacokinetics of a regional chemotherapeutic treatment of gemcitabine administered by the stopXow technique. The stop-Xow concept was introduced in 1993 by Aigner as a semi-invasive loco-regional drug delivery approach [3] : the pharmacokinetic exposure to intra-arterial chemotherapy can be markedly enhanced when the arterial blood Xow is reduced immediately after drug injection. To that purpose, Aigner et al. suggested to inXate a balloon catheter in the main aVerent artery to slow down drug wash-out (arterial inXow occlusion). Pancreatic, gastric and pelvic tumours as well as peritoneal carcinomatosis are the main potential indications for this approach. However, the increase in drug exposure remains limited by the unavoidable drug wash out from the target organ into the venous stream. Thus, in order to further increase drug exposure during stop-Xow, it may be possible, to add a venous outXow occlusion to establish a recirculation perfusion circuit (Fig. 1) . This stop-Xow perfusion technique is well suited for large body segments such as the thoracic and abdominal cavities in the pelvis and the limb [3] [4] [5] .
There is currently controversy regarding the eYcacy of such treatments: the Wrst stop-Xow trials (1993) (1994) (1995) (1996) were promising with overall tumour responses up to 57% [4, 6] , but later trials (1998-present) were unable to conWrm these results [7] [8] [9] [10] . However, the distribution and concentrations of the antineoplastic drugs in the regional and systemic compartments of the circuit have not been thoroughly studied. To the best of our knowledge, only one clinical pharmacokinetic trial has been published in this setting [10] . Given this limited information, there is a need to deWne more precisely the local and systemic disposition of anticancer drugs administered through this manner before phase II or III trials are undertaken.
Gemcitabine chemotherapy is presently the standard of care for advanced pancreatic adenocarcinoma and has a favourable safety proWle when administered systemically. This is why this drug was selected for this "proof-of-con- Fig. 1 Abdominal stop-Xow perfusion (from Pilati et al. [5] ). IVC, inferior vena cava; A, aorta; D, diaphragm cept" study, even though its therapeutic eYcacy under hypoxic conditions is not known.
This phase I study assesses the feasibility and tolerability of a regional treatment of gemcitabine administered by hypoxic abdominal stop-Xow perfusion to patients with advanced pancreatic cancer or refractory malignant ascites. It also describes the regional and systemic pharmacokinetic proWles of gemcitabine and its main metabolite 2Ј,2Ј-diXuorodeoxyuridine (dFdU).
Methods

Patients
This phase I study was approved by the local Ethics Committee of our Institution. At inclusion, all patients suVered from a histologically proven stage II, III or IV carcinoma of the pancreas that had been treated according to current state of the art (resection or bypass surgery, interventional endoscopy or radiology, palliative radiotherapy, systemic chemotherapy). Stage II patients were included in case of residual disease or failure of radical resection; stage III patients were included in all cases, and stage IV patients exclusively if intra-abdominal metastases were the only site of dissemination. Patients suVering from malignant ascites due to intra-abdominal carcinomas, resistant to conventional treatments could also be included. Patients had to be older than 18 years of age, have a performance score of less than or equal to 2 on the Eastern Cooperative Oncology Group (ECOG) scale, and have intact liver and renal function tests. All gave informed written consent and knew that the protocol did not aim at cure. None had signiWcant cardiac failure (New-York Medical Heart Association, classes III and IV), severe disease of the central nervous system (tumours, psychiatric disorders, stroke), peripheral arterial disease (grade II or more according to Fontaine), an organ allograft, haemorrhagic diathesis, active infectious disease, an active peptic ulcer, a history of deep vein thrombosis or a previous radiotherapy treatment involving more than 20% of haematopoietic bone marrow.
Study design
The primary study endpoint was the assessment of the pharmacokinetic proWle and tolerability of gemcitabine administered by stop-Xow perfusion. The evaluation of gemcitabine anti-tumoral eVect was a secondary endpoint. All patients were scheduled to receive subsequent systemic gemcitabine treatments (1,000 mg/m 2 every week for 3 weeks, followed by 1 week oV) after closure of the study.
Three dose levels of gemcitabine were tested in ascending order in three sets of patients. The initial dose level was chosen at 500 mg/m 2 (i.e. 50% of a usual weekly dose by intravenous infusion), and subsequent escalations were by 50% steps (i.e. 750 and 1,125 mg/m 2 ). In case of a dose-limiting toxicity (DLT), an additional three patients had to be treated at the same dose level. Treatment at an escalated dose was only given if less than three of six patients had experienced a toxic adverse event. DLT was deWned as a lasting grade III or any grade IV toxicity according to the common terminology criteria for adverse events (CTCAE) [11] .
Stop-Xow procedure
The stop-Xow procedure was performed under general anesthaesia by introducing an arterial balloon catheter into the aorta via the common femoral artery up to the diaphragm and a venous balloon catheter via the sapheno-femoral junction up to the right atrium under radioscopic and radio-angiographic control (Fig. 1) . Systemic anticoagulation was achieved with heparin (150 U/kg). An extracorporeal circuit (without a blood oxygenator) was then connected, draining the blood from the vena cava and reinfusing it into the aorta. This circuit was primed with 200 ml of Hartmann solution and 5,000 U heparin and started at a Xow rate of 100 ml/min. After checking of the balloons' position, the circulation in the lower limbs was interrupted by pneumatic cuVs at the root of the thighs and aorto-caval Xow block was achieved by inXating the balloon catheters. The Xow of the circuit was set between 100 and 300 ml/min according to blood outXow capacity. A gemcitabine bolus was then injected into the circuit and allowed to circulate in the abdomen until the end of a 20 min stop-Xow period.
At the end, blood circulation was re-established by deXating Wrst the caval catheter balloon, then the aortic one and Wnally by removing the limb cuVs. The balloon catheters were removed and the vessels sutured.
The level of hypoxia reached during the stop-Xow procedure was considered stringent if at least two of the following three criteria were met: pH · 7.2, pO 2 nadir ratio ·0.70 mmHg and pCO 2 peak ratio ¸1.35 mmHg.
Optimization of caval balloon positioning
In spite of an apparently complete venous block at the vena cava's level, as assessed by angiography, transoesophageal ultrasonography revealed residual blood Xow in some patients, which could have caused signiWcant drug leakage into the systemic circulation. In this situation, ultrasonography enabled the surgeon to optimalise the vena cava' balloon position at the level of right atrium.
Clinical follow-up and evaluation
The patients were monitored closely during the month following the stop-Xow procedure and had weekly medical visits. Tolerance of the stop-Xow perfusion with gemcitabine was evaluated for 3 weeks: haematologic parameters were checked three times a week, while renal and hepatic functions were controlled three times during the Wrst week and then weekly. The common terminology criteria for adverse events (CTCAE) was used to grade organ damage [11] .
In patients with pancreas carcinoma, the anti-tumoral eVect was assessed by CT-scan 2 months after treatment and then every 3 months. The markers carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) were checked every month. In case of malignant ascites, the umbilical perimeter was measured and CT-scan evaluation, in case of a tumoral mass, was done as above. Depending on the tumour histology, other markers were also followed.
Pharmacokinetics
Samples
Blood samples were collected into heparinised tubes (Monovettes ® 5.5 ml, Sarstedt, Nümbrecht, Germany) added with 50 l of the cytidine deaminase inhibitor tetrahydrouridine (THU; 1 mg/ml solution) from Calbiochem (supplied by Juro, Luzern, Switzerland). Arterial blood samples were collected from the extracorporeal circuit before and then at 2, 4, 6, 8, 10, 15 and 20 min after gemcitabine injection in the perfusion circuit. Peripheral venous blood samples were collected before and at 2, 4, 6, 8, 10, 15, 20, 25, 30, 35, 40 , 50, 60, 90 min, and then 2, 3, 4, 6 h after gemcitabine injection. Plasma was separated by centrifugation at 1,500g for 10 min. All samples were stored at ¡20°C until analysis.
Analytical method
The plasma concentrations of gemcitabine and its inactive metabolite dFdU were determined by a normal-phase HPLC method with UV detection. Gemcitabine HCl (LY2643689) and dFdU (LY198791) were generously supplied by Eli Lilly (Indianapolis, USA). The related compound lamivudine (3TC ® ) was purchased from GlaxoSmithKline (Mün-chenbuchsee, Switzerland) to be used as internal standard. BrieXy, a 1 ml-sample aliquot was spiked with 100 l of internal standard aqueous solution (12.5 g/ml) prior to the protein precipitation step. Then, 500 l acetone (E. Merck, Darmstadt, Germany) and 50 l zinc sulphate (E. Merck, Darmstadt, Germany) 70% aqueous solution were added. The samples were mixed and centrifuged at 22,000g for 10 min at +4°C. The supernatant was evaporated to dryness at 60°C for 75 min under nitrogen stream and the solid residue was resuspended in 150 l methanol (E. Merck, Darmstadt, Germany) and sonicated for 15 min. The nonsolubilised solid residue was eliminated by centrifugation at 22,000g for 20 min at 4°C. The particle-free samples were introduced into HPLC 0.5 ml amber glass vials (i.e. protected from light) (Laubscher Labs, Miecourt, Switzerland). A volume of 10 l was subjected to HPLC analysis onto a YMC-pack polyamine II column, 250 mm £ 4.6 mm i.d., S-5 m, 12 nm (YMC, Schermbeck, Germany) equipped with a YMC-pack polyamine II guard column, 10 mm £ 4 mm i.d. Wlled with the same packing material (YMC, Schermbeck, Germany). The mobile phase was delivered using a gradient elution of acetonitrile (E. Merck, Darmstadt, Germany) and an aqueous solution containing 30 mM of ammonium formate (Fluka, Buchs, Switzerland) adjusted to pH 5.5 with formic acid 1%: 95/5 at 0 min ! 85/15 at 22 min, ! 0/100 at 27 min, ! 0/100 at 42 min, ! 95/5 at 57 min, ! 95/5 at 65 min delivered at 1 ml/min (0.8 ml/min between 27 and 42 min, washing time). The analytes were detected using a spectrophotometric UV-DAD detector set at 272 nm. The retention times for dFdU, lamivudine and gemcitabine are 11.2, 13.4 and 18.5 min respectively. Calibration curves were obtained by quadratic weighted 1/concentration 2 (1/x 2 ) least-squares linear regression analysis of the peak ratio of gemcitabine and dFdU to internal standard, versus the corresponding concentration ratio in each standard solution. The calibration curves were linear over the range of 0.050-10 g/ml for gemcitabine and 0.075-10 g/ml for dFdU. The method was validated according to the FDA and SFSTP (Société Française des Sciences et Techniques Pharmaceutiques) recommendations [12, 13] as well as the guidelines of the Washington Conference [14, 15] . The method was found to be precise with coeYcients of variation (CV%) within 3.6-6.8%, and accurate with 95% conWdence limits comprised between 6.9 and 13.4% for gemcitabine and dFdU at the three quality control samples' concentration level. The limit of detection was experimentally determined to 0.0125 g/ ml for gemcitabine and 0.01875 g/ml for dFdU.
Pharmacokinetic data analysis
The maximum plasma concentration (C max ) and the time to maximum (t max ) were determined by direct data examination for gemcitabine and dFdU in the extracorporeal system and in the peripheral plasma. The terminal half-life (t 1/2term ) was calculated in the peripheral plasma as Log(2)/ z , where z represents the terminal elimination rate constant, i.e. the absolute value of the slope of the terminal log-linear phase. Gemcitabine and dFdU exposures in the extracorporeal system and in the peripheral plasma during the 20 min of stop-Xow were expressed as the corresponding area under the concentration-time curve (AUC 0-20 ) calculated by the linear trapezoidal rule. The total systemic drug exposure was expressed as the area under the concentration-time curve (AUC 0-1 ) extrapolated to inWnity, deduced from the terminal elimination rate constant z . Regional versus systemic drug exposure ratios were obtained by dividing the regional C max and AUC t0-20 values by the corresponding systemic values for each patient.
All the data were calculated separately for each patient. The results are presented as geometric mean and relative coeYcient of variation (CV, %) at each drug dose level. A Student's T test was used to assess diVerences amongst the PK parameters between patients with and without stringent hypoxia during perfusion. Statistical signiWcance was assumed at P < 0.05.
Results
Patients' characteristics
From September 1997 to October 2002, nine patients were included in the study. Patients' demographics are described in Table 1 . The male/female ratio was 6/3. The median age was 56 years (range 45-71). All patients had a performance status ·2. Eight patients had adenocarcinoma of the pancreas (patients 1-8) including three (patients 1, 5 and 6) with liver metastases at the time of inclusion. One patient (patient 9) suVered from an intrahepatic cholangiocarcinoma with refractory malignant ascites.
One patient (patient 7, dose level 3) was not assessable because of a balloon rupture after 5 min of stop-Xow perfusion: the pneumatic cuVs were immediately deXated and a second stop-Xow perfusion performed 42 min later, but no reliable pharmacokinetic proWle could be obtained.
Hypoxia during stop-Xow
Hypoxia was considered stringent in patients 5, 6, 8 and 9. The other perfusions did not fulWl the criteria for hypoxia to be considered as stringent. The evolution of pH, pO 2 and pCO 2 during stop-Xow are shown on Fig. 2a-c (the pH, pO 2 and pCO 2 data of patient 1 could not be included in Fig. 2 because of doubts regarding collection times for blood gases testing; however, hypoxia in this patient was assessed as non-stringent). When considering the entire series of experiments, it is to be noticed that hypoxia was more often stringent in the latest patients. This may be the result of improvements in the positioning of the atrial balloons thanks to transoesophageal ultrasonography.
Pharmacokinetic analysis
Gemcitabine pharmacokinetics
During the 20 min of stop-Xow perfusion, very high levels of gemcitabine were rapidly reached in the abdominalextracorporeal circuit (Fig. 3a) . The average C max values achieved in the circuit were 246, 2,039 and 4,780 g/ml for the three dose levels (500, 750 and 1,125 mg/m 2 ), respectively (Table 2 ). Such C max were 6 to 655-fold higher than those measured in the peripheral plasma (average ratio 70, CV 423%). The AUC 0-20 values measured in the stop-Xow circuit during perfusion exceeded by a factor of 3-333 those obtained in the peripheral circulation (average ratio 32 , CV 452%). Abdominal exposure to gemcitabine was thus much higher than systemic exposure.
However, gemcitabine concentration-time proWles in the peripheral plasma (Fig.3b) indicate that a signiWcant leakage occurred towards the systemic circulation throughout stop-Xow perfusion. No burst in peripheral plasma concentration was observed at the end of the perfusion, when the balloons and cuVs were deXated. Interestingly, gemcitabine plasma levels were lower during the Wrst 15 min of perfusion in the group whose stop-Xow procedure was performed under stringent hypoxia (patients 5, 6, 8 and 9), even though they were receiving the upper dose levels (i.e. level 2 for patients 5 and 6, and level 3 for patients 8 and 9): this may be explained by an improved isolation of the extracorporeal circuit, due to the optimal sonographically assisted atrial positioning of the venous balloon. Further analysis conWrmed that the regional exposure to gemcitabine was statistically higher when hypoxia was stringent (P = 0.004 for C max and P = 0.002 for AUC 0-20 , both normalised to gemcitabine dose). The achievement of stringent hypoxia markedly increased the regional to systemic concentration ratio (P = 0.02 for C max regional/systemic ratio and P = 0.03 for AUC 0-20 regional/systemic ratio): this single factor explains 60% of the relative variability in both ratio values, as the level of hypoxia is directly related to the degree of vascular occlusion during stop-Xow. 
dFdU pharmacokinetics
QuantiWable levels of dFdU, although lower than those of gemcitabine, were found in the abdominal circuit and in the peripheral plasma from the beginning of the stop-Xow procedure. This represents gemcitabine rapid metabolism into dFdU in both compartments (Fig. 3d) . The ratio of AUC 0-20 of dFdU over gemcitabine was about ten times higher in peripheral blood, suggesting either a more eYcient bioinactivation of gemcitabine in the systemic compartment, or less probably a stronger elimination of dFdU in the abdominal-extracorporeal circuit. The dFdU concentration-time proWle in peripheral plasma during stop-Xow perfusion and up to 420 min after the beginning of the perfusion is shown in Fig. 3e-f . Like gemcitabine, dFdU exhibits a Wrst order elimination rate but has a longer t 1/2term of 248 min. The remaining pharmacokinetic parameters are listed in Table 2 .
Tolerability and toxic eVects
The regional chemotherapy treatment by stop-Xow perfusion was generally well tolerated. There was no technical or haemodynamic complication during the surgical procedure other than the balloon rupture in patient 7 described above. Table 3 . There were no grade 4 toxicities. Grade 3 toxicities were mostly hepatic. No renal (creatinine) grade 3 and 4 toxicity was noted. All grade 3 toxicities (haematologic and hepatic) are listed in Table 3 .
Concentration-toxicity relationships were also investigated. A positive signiWcant correlation (r = 0.84 and 0.87, P < 0.05) was found between the systemic C max of gemcitabine and the nadir of both leucocyte and neutrophile counts.
Responses and survival
Eight patients were evaluated for tumour response by abdominal CT 1 month after the stop-Xow perfusion. This evaluation was global, in the sense that the patients received only one hypoxic perfusion that was followed by systemic gemcitabine treatments. One patient could not be assessed due to clinical progression of the disease and early death 33 days after the stop-Xow perfusion. Four patients had radiological progression of the disease: two of them developed liver metastases and one bone metastases (patient 6). Two patients had stable disease. Patient 9 (with cholangiocarcinoma of the liver) had a stable abdominal-CT picture of the hepatic tumours, but with increased ascites; the disease then progressed rapidly and the patient died 2.5 months after the stop-Xow procedure.
The results available for the cancer markers CA 19-9 and CEA, did not indicate any decrease in tumour burden during the Wrst month after stop-Xow perfusion.
According to a Kaplan-Meier analysis, the median survival from the time of inclusion was 2.9 months (95% conWdence interval: 1.4-17.7 months).
Discussion
Stop-Xow therapeutic approaches are based on the assumption that neoplasms conWned to one anatomical compartment can be exposed to high local concentrations of anticancer agents by using arterial and venous balloon catheters connected to an extracorporeal perfusion circuit without oxygenation. The present study reports the feasability, tolerability and pharmacokinetic proWles of gemcitabine and its main metabolite, dFdU in nine patients. One patient has been excluded because of a balloon rupture that occurred during the stop-Xow procedure. In our little study group, the characteristics of the patients were relatively heterogeneous: eight patients had advanced adenocarcinoma of the pancreas, with three of them having liver metastases, and one suVering from an intrahepatic cholangiocarcinoma with refractory malignant ascites. The pharmacokinetic assessments performed proved that the exposure to gemcitabine was indeed markedly higher in the regional circuit than in the peripheral plasma. The exposure was, however, signiWcantly greater for patients perfused under stringent vascular isolation conditions, inducing deep hypoxia. In our study, the regional over systemic ratios of AUC 0-20 measured under non-stringent hypoxic conditions (range 2.7-49) were signiWcantly lower than those measured under stricter hypoxic conditions. The latter values were much higher (range 23-333) than those reported in literature for comparable abdominal or pelvic stop-Xow perfusions [7, 10, [16] [17] [18] . Meyer et al. for example, reported an AUC ratio of 4 [10] and Petrowski et al. of 6.5 after abdominal stop-Xow of mitomycin C [7] . In the limited number of studies available, various drugs such as mitomycin C and doxorubicin were administered by stopXow perfusion, which makes comparisons with gemcitabine diYcult. However, our study highlights that hypoxic conditions are related to the degree of vascular isolation of the regional circuit. This deserves, therefore, very close monitoring which is best achieved by transoesophageal ultrasonography: to the best of our knowledge earlier studies did not use this technique.
In the present study, the C max levels of gemcitabine measured in the circuit were very high (up to 5,129 g/ml). By comparison, systemic i.v. administration of similar doses has been reported to yield peak plasma concentrations of 30-40 g/ml [19] [20] [21] [22] [23] [24] [25] [26] [27] . As the intracellular phosphorylation of gemcitabine is known to be saturable [19] , the beneWt of very high gemcitabine levels remains questionable. Others have indeed shown that gemcitabine peak levels of 4-5 g/ ml enable a maximal production rate of the pharmacologically active gemcitabine triphosphate that accumulates in mononuclear cells [19] . Higher levels may then saturate the rate of cellular accumulation in a majority of patients. It is, however, not known whether gemcitabine disposition in mononuclear cells is similar to that in tumour cells. In addition, eYcient penetration into solid tumours may require higher gemcitabine plasma levels. The transport and cellular metabolism of gemcitabine in cancer tissues and solid tumour masses deserve therefore further research. The average systemic C max , t 1/2term and AUC 0-1 levels of gemcitabine and dFdU, according to the delivered dose, compare well with the pharmacokinetic data reported in the Table 3 Toxicities according to the common terminology criteria for adverse events (CTCAE) [19] 
literature [19] [20] [21] [22] [23] [24] [25] [26] [27] . This indicates that a 20 min stop-Xow procedure does not signiWcantly modify the overall systemic exposure to gemcitabine and its metabolite. The toxicities encountered were acceptable considering the complexity of the procedure. We did not observe increased toxicities in the four stringent perfused patients. However, as this sub-group is very small, the tolerability of the procedure should be interpreted with some caution. Overall the toxicities were mostly hepatic, but it remains diYcult to diVerentiate between the respective contributions of systemic and regional exposures. Liver toxicities may be favoured by the stop-Xow procedure itself, by hypoxia and/or by the very high regional gemcitabine concentrations. Studies in liver transplantation may give a clue as they indicated that the liver is highly sensitive to the reperfusion injury mediated by reactive oxygen species [28] . In addition, gemcitabine itself is known to cause transient elevations of liver function tests after i.v. administration in two-thirds of patients and may therefore have contributed to the observed toxicities [29] . Interestingly, we did not observe any gall bladder toxicity, contrary to other authors who perform stop-Xow with mitomycin C for liver metastases: in their study, hypoxia was essentially toxic for the gallbladder, with ischemic cholecystitis occurring in 3/15 cases (14%) [30] . Finally, it seems that the drugs used for general anaesthesia, including halogenated agents may also play a signiWcant role in the observed hepatotoxicity. In brief, several reasons, taken separately or together, may be incriminated for the liver function tests elevations but we feel that hypoxia was the major cause.
Even though the clinical response was not a primary endpoint in this phase I study, the absence of any objective therapeutic response is disappointing. This may actually have been expected because gemcitabine, although the standard of care in advanced adenocarcinoma of the pancreas, is prescribed on the basis of an improved quality of life, with a very short actual survival increase compared to 5-FU (5.6 vs. 4.4 months) [31] . Such survival data are therefore in line with our median survival of 2.9 months (95% conWdence interval 1.4-17.7 months). This result highlights the current lack of eYcacious treatment for a malignancy with a disastrous prognostic.
In conclusion, gemcitabine may not have been the best choice in the setting of terminal pancreatic cancer, due to its questionable activity under hypoxic conditions. As cellular bio-activation into gemcitabine-triphosphate is an energy-dependent process, it may decrease under hypoxia. This, in turn, may slow down DNA synthesis and protect tumour cells against drug action. However, our study demonstrates that the stop-Xow procedure was safely performed on these nine patients with various advanced abdominal malignancies. The toxicity was evaluated as acceptable until a dose level of 1,125 mg/m 2 and the regional exposure to an anticancer agent could be enhanced dramatically using an optimised perfusion technique. In the future, it should be possible to treat patients with this approach using bioreductive drugs such as mitomycin C, melphalan, or tirapazamine-a more recently developed agent currently under clinical development [32] . Another promising strategy may consist in delivering hypoxia-selective gene therapy or targeted therapy directed against the hypoxia inducible factor 1 (HIF-1), expressed at high levels in most cancer cells [33] . Before assessing whether these new drugs improve the response to chemotherapy, another phase I trial with escalating doses would be warranted in order to study their toxicity.
